Bicycle Therapeutics (BCYC) awards CFO 60,000 stock options at $4.21
Rhea-AI Filing Summary
Bicycle Therapeutics PLC Chief Financial Officer Travis Alvin Thompson received a grant of employee stock options for 60,000 Ordinary Shares on July 15, 2026. The options have an exercise price of $4.2100 per share, expire on July 15, 2036, and vest 25% on July 15, 2027 with the balance in 36 equal monthly installments.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Thompson Travis Alvin
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 60,000 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 60,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options Granted: 60,000 options
Exercise Price: $4.2100 per share
Underlying Ordinary Shares: 60,000 shares
+3 more
6 metrics
Options Granted
60,000 options
Employee stock options granted to the CFO on July 15, 2026
Exercise Price
$4.2100 per share
Exercise price for each option covering Ordinary Shares
Underlying Ordinary Shares
60,000 shares
Each option is exercisable into one Ordinary Share
Expiration Date
2036-07-15
Date on which the granted stock options expire
Initial Vesting Date
2027-07-15
One-fourth of the total option shares vest on this date
Remaining Vesting Period
36 months
Remaining shares vest in 36 equal monthly installments after initial vesting
Key Terms
Employee Stock Option, exercise price, vesting, Ordinary Shares
4 terms
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"conversion_or_exercise_price of 4.2100 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"option shall vest with respect to one-fourth of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did BCYC report for CFO Travis Alvin Thompson?
Bicycle Therapeutics PLC reported that Chief Financial Officer Travis Alvin Thompson received a grant of 60,000 employee stock options on July 15, 2026. These options relate to Ordinary Shares of the company and are held as direct ownership.
How many options were granted to the BCYC CFO and at what exercise price?
The CFO was granted 60,000 employee stock options, each with an exercise price of $4.2100 per share. These options give him the right to buy Bicycle Therapeutics PLC Ordinary Shares at that fixed price until their expiration date.
What is the vesting schedule for the BCYC CFO’s 60,000 stock options?
The option grant vests as follows: one-fourth of the total shares vest on July 15, 2027, and the remaining shares vest in 36 equal monthly installments thereafter. This creates a four‑year vesting period tied to continued service.
When do the BCYC CFO’s newly granted stock options expire?
The employee stock options granted to the CFO expire on July 15, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Bicycle Therapeutics PLC Ordinary Shares at the $4.2100 exercise price.
Did Bicycle Therapeutics PLC indicate use of a Rule 10b5-1 plan for this BCYC Form 4?
No. The Form 4 indicates the Rule 10b5‑1 checkbox is not marked, meaning this reported option grant was not affirmatively identified as being made under a Rule 10b5‑1 trading plan in the filing’s cover representations.
What is the total number of derivative securities held by the BCYC CFO after this grant?
Following this transaction, the CFO is reported as directly holding 60,000 derivative securities in the form of employee stock options. Each option is exercisable into one Bicycle Therapeutics PLC Ordinary Share, subject to the vesting schedule and the $4.2100 exercise price.